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NOVELTY AND IMPACT OF THE WORK 
We describe for first time overexpression of ErbB3 in Germ cell testicular 
tumors (GCTs). Moreover our results in vivo using an orthotopic model explain 
the complete lack of effect (refractoriness) to pure ErbB1 receptor inhibitors 
caused by an ErbB1-independent activation of ErbB2. In contrast, the dual 
inhibitor of ErbB1 and ErbB2 lapatinib is effective blocking tumor growth and 
could be a new alternative for treatment of those patients who are refractory to 
cisplatin (CDDP)-based chemotherapy. 
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 ABSTRACT 
In this work we have analyzed the expression of different members of the ErbB 
family in human samples of germ-cell testicular tumors (GCTs). We observed 
expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found 
overexpression of ErbB3 in all GCTs tested. This pattern of expression was 
maintained when primary tumors were orthotopically implanted in nude mice. 
We have chosen a choriocarcinoma model characterized by high levels of 
ErbB1, but also of ErbB2 and ErbB3, to assay the in vivo effect of ErbB 
inhibitors on tumoral growth. Our results showed a complete lack of effect 
(refractoriness) to the pure ErbB1 receptor inhibitors cetuximab and gefitinib. 
While these inhibitors blocked ErbB1 phosphorylation, ErbB2 phosphorylation 
was not affected, suggesting an ErbB1-independent activation of this receptor. 
In order to confirm the importance of ErbB2 activation, animals were treated 
with lapatinib, a dual ErbB1 and ErbB2 inhibitor. Lapatinib treatment caused a 
50% inhibition in tumor growth, an effect correlated with a blockade of both 
ErbB1 and ErbB2 phosphorylation levels, and of downstream signalling 
pathways (Akt, ERKs and Stat3). ErbB2 activation could still occur due to the 
formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely 
inhibited by lapatinib. Our results explain why lapatinib but not anti-ErbB1 
agents might be effective for treatment of GCT patients.  
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INTRODUCTION 
The ErbB family of tyrosine kinase receptors includes ErbB1/EGFR, 
ErbB2/Neu/Her-2, ErbB3 and ErbB4. Ligand binding induces homo or 
heterodimerization between ErbB receptors, which leads to the activation of 
their intrinsic tyrosine kinase activity, autophosphorylation of intracellular 
tyrosine residues and activation of multiple signal transduction cascades 1, 2. 
ErbB2 lacks ligand-binding capacity, whereas ErbB3 is intrinsically inactive or at 
least, weakly active as a kinase 3. Both of them heterodimerize with other ErbB 
family members to activate intracellular signalling 4. 
Altered ErbB signalling has been implicated in the development of 
different tumor types 5, 6. Furthermore, in some studies ErbB1 or ErbB2 aberrant 
expression has been associated with a poor prognosis and resistance to 
conventional therapies 4, 7-9. The implication of ErbBs in tumor progression has 
turned these receptors into some of the most studied molecular targets in 
clinical oncology. There are two main classes of ErbB receptor inhibitors: 
monoclonal antibodies (mAbs) 10, 11 and small molecule tyrosine kinase 
inhibitors (TKIs) 4. Targeted therapies against ErbBs have been successfully 
used in the treatment of some advanced breast, colorectal and non-small-cell 
lung cancers. FDA-approved drugs that inhibit ErbBs include two mAbs against 
ErbB1 (Cetuximab and Panitumumab), two mAbs against ErbB2 (trastuzumab 
or herceptin and pertuzumab); and four TKIs, two that specifically inhibit ErbB1 
(Erlotinib, Gefitinib) and lapatinib that inhibits ErbB1 and ErbB2 9. 
Germ cell tumors (GCTs) of the testis are the most common solid 
malignant neoplasm in young adult males aged 15 to 40 years old, and 
represent the leading cause of cancer-related mortality and morbidity in this age 
group 12. Testicular GCTs are divided into seminoma and non seminomatous 
germ cell tumors based on histological, biological, and clinical features. Non 
seminomatous GCTs include one or more of the following components: 
teratoma, embryonal carcinoma, teratocarcinoma, yolk sac tumor and 
choriocarcinoma, the last one being the most aggressive component of mixed 
GCTs 13, 14. ErbB1 and 2 expression seem to be restricted to non seminomatous 
germ cell tumors 14-16, but the exact contribution of ErbBs in the development, 
differentiation and progression of these tumors is not known. Our results show 
that most GCTs express high levels of ErbB3. This ErbB3 expression explains 
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tumor resistance to pure ErbB1 inhibitors, in contrast to positive effects of 
multiple ErbBs inhibition caused by lapatinib. 
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MATERIALS AND METHODS 
Chemical Compounds 
Cetuximab (Erbitux®) was obtained from Merck. Gefitinib (Iressa®) was 
kindly provided by AstraZeneca and Lapatinib (Tyverb®) was kindly provided by 
GlaxoSmithKline. Both were dissolved in 0,5% carboxymethylcellulose - 0,1% 
Tween 80 (Sigma) solution. 
 
Orthotopic implantation of testicular tumors 
Male nu/nu Swiss mice were purchased from Harlan (Spain). For our 
studies several orthotopic testicular germ cell tumors models (TGTs) were used, 
originated from tumor patients: three embryonal carcinomas, two with 
heterogenous tumor histological compounds, one yolk sac and two 
choriocarcinomas, among them the TGT38. This last model and the surgical 
implantation methodology was previously described in Castillo-Avila et al 17. 
 
Treatment schedule 
Treatments started when a palpable intra-abdominal mass was detected 
(14 days); studies were terminated when tumors in vehicle-treated animals were 
judged to adversely affect their well-being. Mice were sacrificed by CO2 
inhalation and the effects of the different treatments on tumor response were 
evaluated by determining tumor weight and volume, where 
Volume=(length)(width2/2). 
For the first treatment schedule five mice were treated with gefitinib, 
administered daily orally, for five consecutive days, at doses of 100 mg/kg. Four 
mice were treated with 1 mg cetuximab twice a week by intraperitoneal 
administration. As control group four mice received daily oral vehicle solution 
and intraperitoneal sterile serum at the same schedule as gefitinib and 
cetuximab mice. Mice were treated for 11 days.  
For second treatment schedule, seven mice were treated with lapatinib 
100 mg/kg administered daily orally. Nine mice were treated with vehicle oral 
solution with the same schedule as the lapatinib group. Mice were treated for 13 
days.  
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None of these treatments had a significant effect on the body weight of 
mice, and animals appeared healthy and active throughout the duration of the 
study 
 
Histological study 
Representative fragments of the primary and xenografted tumors were 
fixed in buffered formalin, dehydrated and embedded in paraffin. Tissue 
sections (3-4 µm) were stained with hematoxylin-eosin for morphological 
analysis.  
Anti-ErbB1 mouse monoclonal antibody (1:50) (ZYMED laboratories, 
31G7), anti-ErbB2 mouse monoclonal antibody (1:100) (Novocastra, NCL-L-
CB11) and anti-ErbB3 rabbit polyclonal antibody generated by Dr.Pandiella 
(1:75) 18 were used for immunohistochemical characterization. Previous to 
primary antibody incubation, tissue sections were permeabilized with saponin, 
for ErbB1 staining, and with pepsin for ErbB2 staining. Slides were incubated 
with the secondary antibody anti-mouse (DAKO envision+ System-HRP), and 
the detection was done with the DAB+ Chromogen System (DAKO). The slides 
were then dehydrated and mounted.  
OCT-frozen tissue sections from control and treated tumors were used 
for immunofluorescence staining carried out to detect Ki67 positive cells and 
apoptotic cells by TUNEL staining as described 17. 
Images of sections were obtained on an Olympus-BX60 microscope. To 
quantifiy Ki-67 and TUNEL staining six hotspot fields in viable tissue zones at 
x400 magnification were captured for each tumor. Quantification of staning 
areas was done using ImageJ software.  
 
Western blotting 
Western blot from samples from different treated tumors were performed 
as described 17.  
Blots were incubated with polyclonal rabbit anti-phospho tyrosine 1173 
ErbB1 antibody (Cell Signaling), polyclonal rabbit anti-ErbB1 antibody (Santa 
Cruz), polyclonal rabbit anti-phospho ErbB2  (Neu-sc18, Santa Cruz) antibody, 
polyclonal rabbit anti- ErbB2 antibody (Santa Cruz), polyclonal rabbit anti-
phospho tyrosine 1289 ErbB3 antibody (Cell Signaling, Beverly, MA), polyclonal 
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rabbit anti-ErbB3 antibody (C-17, Santa Cruz), mouse monoclonal anti-
phospho-ERK antibody (Sigma), rabbit anti-Erk1/2 total 19, rabbit polyclonal anti-
phospho-Akt (Ser 473) antibody (Cell Signaling), rabbit polyclonal anti-AKT 
(Cell Signalling), rabbit polyclonal anti-phospho-Stat3 (Tyr705) (D3A7) antibody 
(Cell Signaling), monoclonal mouse anti-actin antibody (Sigma Chemical) or 
monoclonal mouse anti-tubulin antibody (Sigma Chemical) in 1/5 blocking 
solution overnight at 4°C. 
Densitometry quantification was carried out using the Quantitiy One (BioRad 
Laboratories, INC) software. 
 
Quantitative real-time PCR 
Real-time PCR of cDNA obtained from TGT38 independent tumors and 
human testis was done as described 17, with the exception of hErbB1 primers, 
where the annealing was carried out at 61ºC. Human specific primers used are 
ErbB1 (5’-GTCCCATAGTTGGACAGGATG and 5’-
TCATCAGGGGAAATGCTCTT), ErbB2 (5’-AGGGGTCTTGATCCAGC and 5’-
GGTTGGTGTCTATCAGTGTGA), ErbB3 (5’-GCTTGCTTTTCAGCCTGGCC 
and 5’-TTCTCAGCATCGCCGGTCAC), ErbB4 (5’-
GTACAGTGCTGACCCCACCG and 5’-AGGGTTCTCCTCCACTGGATTCA) 
and the house keeping gene β-actin (5’GAGGCAGCCAGGGCTTA  and 
5’AACTAAGGTGTGCACTTTTATTCAACT). 
 
Immunoprecipitation 
To immunoprecipitate ErbB1 or ErbB2 and ErbB1- or ErbB2-associated 
proteins, TGT38 tumors were mechanically disrupted and lysed using RIPA 
lysis buffer as described. Tumor lysates, with 750 µg of total protein, were first 
precleaned by incubation for 4h at 4ºC on the orbital shaker with 60 µl of protein 
A-Sepharose beads (GE, Healtcare) and 60 µl of protein G-Sepharose beads 
(GE, Healtcare). Beads were then discarded after centrifugation, and lysates 
were incubated with 1,6 µg of the rabbit polyclonal anti-ErbB1 antibody (Santa 
Cruz) or 1,6 µg of the rabbit polyclonal anti-ErbB2 antibody Neu (sc18): SC-284 
(Santa Cruz) over-night at 4ºC on the orbital shaker; with the exception of the 
negative controls, that were incubated without antibody. Then lysates were 
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incubated for 6 h at 4ºC on the orbital shaker with 60µl of protein A-Sepharose 
beads (GE, Healtcare) and 60 µl of protein G-Sepharose beads (GE, 
Healtcare), previously cleaned with RIPA buffer. Immunoprecipitates were then 
collected by centrifugation, washed five times with RIPA buffer at 4ºC and 
denatured in SDS loading buffer for electrophoresis 2X. Then the 
immunoprecipitates were analysed by western blot as described previously.  
 
Statistical analyses.  
Statistical significance of differences in different parameters was 
determined using the Mann-Whitney U test. In all experiments, differences were 
considered statistically significant when p < 0.05.  
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RESULTS 
 
Lack of effect of pure ErbB1 receptor inhibitors cetuximab and gefitinib on 
germ cell testicular growth 
 In order to assay the effect of inhibitors of ErbB1 on germ cell tumoral 
growth, first we evaluated the presence or absence of ErbB1 in different 
orthotopically-derived xenografted non seminoma testicular tumors in from 
different patients of nude mice (TGTs). We analyzed ErbB1 expression levels 
by western blot in samples from these TGTs, and were compared with ErbB 
expression in normal human testicle (Fig. 1A). We detected high expression of 
ErbB1 in choriocarcinoma and in tumors formed by heterogenous compounds, 
as compared to levels expressed in normal human testicle. Lower levels of 
ErbB1 were present in embryonal carcinoma and yolk sac tumors. We also 
immunodetected presence or absence of ErbB2, that was also expressed at 
different levels in most of our GCT samples and their orthotopic-derived models. 
We chose choriocarcinoma TGT38, an orthotopic tumor that expressed 
high levels of ErbB1 receptor, for our in vivo studies. We evaluated the effect of 
cetuximab, a monoclonal antibody anti-ErbB1, or gefitinib, a small molecule 
inhibitor of the tyrosine kinase activity of ErbB1, on the TGT38 tumor growth. 
After tumor implantation we treated mice with these inhibitors, and at the end of 
the treatment tumor volume was measured. No effects on the choriocarcinoma 
tumoral growth were observed for any of the treatments (Fig. 1B). We confirmed 
the lack of effect of cetuximab or gefitinib by measuring tumoral cell proliferation 
(Ki67 positive cells), with similar values for controls compared with both 
treatments (Sup. Fig. S1A), and by measuring tumoral apoptosis (TUNEL 
assay) where we also obtained the same level of apoptotic cells in control 
tumors as compared to cetuximab- or gefitinib-treated tumors (Sup. Fig. S1B). 
These results indicated a lack of effect of pure ErbB1 inhibitors on 
choriocarcinoma germ cell testicular tumor growth in our orthotopic model. 
 
Cetuximab and gefitinib block ErbB1 but not ErbB2 phosphorylation 
 Given the lack of effect of ErbB1 inhibitors on choriocarcinoma growth, 
we then attempted to confirm the inhibitory effect of cetuximab or gefitinib on 
ErbB1 tyrosine kinase activity. We measured by western blot ErbB1 
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phosphorylation in tyrosine 1173, one of the main tyrosines autophosphorylated 
when ErbB1 is active 5, 20. Our results showed that this tyrosine was 
phosphorylated in control tumors while, as expected, its phosphorylation level 
was clearly decreased by cetuximab treatment (52% inhibition) or by gefitinib 
treatment (80% inhibition), in the absence of any effect on total levels of ErbB1 
(Fig. 2A and Sup. Fig. S1C). 
 As is well known, ErbB1 receptor forms heterodimers with ErbB2, with 
cross phosphorylation and cross activation between receptors 4. As our germ 
cell testicular TGT38 tumor model also express ErbB2 (Fig. 1A), so we studied 
the effect of these inhibitors on ErbB2 phosphorylation. As is shown in Fig. 2B 
and Sup. Fig. S1C, ErbB2 was phosphorylated in control tumors, but treatment 
with cetuximab or gefitinib did not significantly affect levels of phosphoErbB2. In 
order to evaluate whether activated ErbB2 was able to signal to downstream 
pathways important for cell proliferation and survival, we measured activity 
levels of three key signalling pathways: Akt (dowstream kinase activated by 
PI3K), ERKs and STAT3 21. Analysis by western blot of phosphorylated proteins 
in these three pathways revealed no detectable effect of cetuximab or gefitinib 
in the levels of phosphoAkt, phosphoERKs or phosphoSTAT3 (Fig. 2C, 2D and 
2E and Sup. Fig. S2A). Our results indicated that ErbB2 was still active in 
presence of pure ErbB1 inhibitors and pathways downstream of ErbBs 
maintained their normal levels of activation. 
 
Lapatinib, a dual ErbB1 and ErbB2 inhibitor, block choriocarcinoma 
tumoral growth 
Taking into account the persistent ErbB2 activation, even in presence of 
cetuximab or gefitinib, we decided to assay a dual tyrosine kinase inhibitor for 
ErbB1 but also ErbB2, lapatinib 9. We repeated the experiment performed with 
the pure ErbB1 inhibitors, this time treating mice with the dual ErbB1 and ErbB2 
inhibitor. Lapatinib caused a 50% inhibition of tumoral volume growth (Fig 3A), 
an effect correlated to a significant block of cell proliferation (80% decrease of 
Ki67 positive cells) and a significant increase in apoptosis (3.5 fold) (Fig. 3B and 
3C). 
Then, the expression levels of activated ErbB1 and ErbB2 were analysed 
in control and lapatinib treated tumors by western blotting. As expected, 
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lapatinib caused a 95% decrease in levels of phospho-ErbB1 and an 80% 
decrease in levels of phospho-ErbB2 (Fig. 4A, 4B and 4C). Using the same 
samples, we also measured levels of activation of downstream signalling 
pathways Akt, ERKs and Stat3 (Fig. 4D, 4E and 4F and Sup. Fig. S2B). 
Lapatinib significantly inhibited levels of phosphoAkt, phosphoERKs and 
phosphoStat3, in contrast with the lack of effect of cetuximab and gefitinib. 
  
ErbB3 is overexpressed in germ cell testicular tumors  
As indicated by our results, ErbB2 activity was normal in the absence of 
ErbB1 activity (Fig. 2). As is well known, ErbB2 can also form heterodimers and 
become activated by other ErbB family receptors. Thus presence and activation 
of other ErbB receptors in these tumors could explain the ErbB2 maintained 
activity observed in our tumoral models treated with ErbB1-pure inhibitors. In 
order to confirm or discard this hypothesis, first we measured by RT-PCR 
mRNA levels for ErbB1, ErbB2, ErbB3 and ErbB4, comparing their levels in 
TGT38 tumors with levels in normal human testis. As shown in Fig. 5A, we 
detected overexpression of ErbB1 and ErbB2 mRNA levels in TGT38 as 
compared to normal testis. But more interesting, we detected an overexpression 
of ErbB3 mRNA levels, 16-fold higher than normal testicle levels. In contrast, 
ErbB4 mRNA was not expressed in our choriocarcinoma tumor model. ErbB1, 
ErbB2 and ErbB3 overexpression were confirmed by western blot comparing 
independent TGT38 tumor samples to independent human testicle samples 
(Fig. 5B). 
Next, we analyzed ErbB3 and ErbB4 expression levels by western blot in 
samples from different TGTs orthotopically-derived models from different 
patients, and were compared with ErbBs expression in normal human testicle 
(Fig. 5C). We found that ErbB3 was overexpressed in all non seminoma 
testicular tumoral models analyzed including choriocarcinomas, yolk sac, 
embryonal carcinoma or tumors formed by heterogenous compounds, as 
compared to normal testicle. In contrast, ErbB4 was expressed at similar levels 
to normal testicle in the different TGTs analyzed except in choriocarcinomas, 
were its expression was even lower than in normal testicle (Fig. 5C). 
In order to confirm the overexpression of ErbB3 in non seminoma 
testicular tumors from patients, we performed immunohistochemical analysis 
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comparing expression of the different ErbBs on different primary tumors 
obtained from patients with their orthotopically grown derived xenografted 
tumors in nude mice. As observed in Fig. 5D, all primary tumors analyzed, 
regardless of their distinct histological components (choriocarcinoma, 
embryonal carcinoma or yolk sac), expressed ErbB1, ErbB2 and ErbB3 at 
different levels, with ErbB1 more expressed in choriocarcinomas and ErbB2 in 
embryonal carcinoma tumors. When we analyzed the expression of ErbB3 we 
detected high levels of this receptor in all tumors analyzed. The expression 
pattern for the different ErbB members was maintained when primary tumors 
from patients were orthotopically implanted in nude mice. 
 
ErbB3 activation depends on ErbB2 in germ cell testicular tumors 
Taken account ErbB3 overexpression that we detected in GCTs, it is very 
likely then that ErbB3 would form heterodimers with ErbB2 in these tumor 
models. In order to show this was the case, we immunoprecipitated ErbB1 or 
ErbB2 from our samples and identified by western blot the members of the ErbB 
family that dimerize with these receptors (Fig. 6A and 6B). Our results indicate 
very low levels of ErbB2 or ErbB3 in immunoprecipitates of ErbB1. In contrast, 
while ErbB1 was present at very low levels in immunoprecipitated ErbB2, ErbB3 
levels were high, suggesting that in our tumoral testicular model ErbB2 
preferntially forms heterodimers with ErbB3.  
Finally, we decided to analize the activation status of ErbB3 in TGT38 
tumors after different treatments. First we examined phosphoErbB3 levels in 
control tumors and tumors treated with lapatinib, gefitinib or cetuximab. Our 
results indicated a complete block of ErbB3 activation with lapatinib treatment 
(Fig. 6C and 6D), while in tumors treated with cetuximab or gefitinib 
phosphoErbB3 levels were not affected (Fig. 6E and 6F). These results 
suggested that in our tumoral model activation of ErbB3 depends on ErbB2 
activation. In all, our results confirmed the existence of ErbB2/ErbB3 
heterodimers and their capacity to signal. 
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DISCUSSION 
 
 In this work we have shown that pure ErbB1 inhibitors are not effective in 
a model of choriocarcinoma testicular tumor that overexpresses ErbB1, 
presumably due to maintained, ErbB1-independent ErbB2 activity. On the 
contrary, when activity of both receptors is blocked by the use of lapatinib, 
tumor growth is compromised. In the absence of ErbB1, ErbB2 can maintain its 
activity through the formation of active heterodimers with ErbB3. 
The ErbB family of receptors not only plays a key physiological role 
during embryonic development and for adult tissue homeostasis, but also their 
normal functions are altered in many types of cancer. Thus, ErbB1 and ErbB2 
receptor expression and activity are increased in different tumors, including 
head and neck, non small cell lung cancer, colorectal, breast and bladder 4. For 
this reason, different targeted drugs have been developed against these 
molecules and some of them are currently used in the clinic, such as cetuximab, 
trastuzumab, gefitinib or erlotinib. However, it is not yet clear how co-expression 
of different members of the ErbB family in the same tumor might affect the 
response to these drugs. In our study, we have used a preclinical model of 
human choriocarcinoma testicular germ cell tumor orthotopically grown in nude 
mice which expresses high levels of ErbB1, but also ErbB2 and, as we have 
shown, ErbB3, to analyze its response to different ErbB-targeted drugs. When 
we treated this tumor with the pure ErbB1-inhibitors cetuximab or gefitinib, both 
failed to affect tumoral growth, even when ErbB1 activation was clearly 
inhibited. This was likely due to the fact that blockade of ErbB1 activation with 
these drugs did not significantly affect the various ErbB-dowstream signalling 
pathways essential for cell proliferation and/or survival, such as ERKs, Stat3 or 
PI3K. When we inhibited both ErbB1 and ErbB2 activity by using the dual 
inhibitor lapatinib, the activity of the PI3K, ERKs and Stat3 pathways was 
reduced and tumoral growth compromised. Re-activation of these signalling 
pathways is the typical mechanism to generate acquired resistance to ErbB-
targeted therapies 22. There are several mechanisms that the tumor might use 
to re-activate these dowstream signalling components. For example, non small 
cell lung cancer patients acquire resistance to gefitinib or erlotinib treatment by 
selection of cells containing an ErbB1 mutant (T790M) 23; some cancer cell lines 
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become resistant to cetuximab by overexpression of ErbB2 or the ErbB3-ligand 
heregulin 24; non-small cell lung cancer cells may become resistant to gefitinib 
by Met receptor amplification and consequently increased ErbB3 activation 25; 
ErbB2-positive breast cancer cells become resistant to trastuzumab by 
overexpression of ErbB1 and its ligands (EGF, TGF-α and HB-EGF) 26; and 
also ErbB2-positive breast cancer cells acquire resistance to gefitinib by 
restoration of ErbB3 phosphorylation 27. Similar mechanisms could also explain 
initial resistance to these drugs (de novo resistance or refractoriness), as in 
head and neck cancer cells, where initial resistance to gefitinib is predicted by 
levels of active ErbB2 and total ErbB3 28; or in prostate cancer cells where pure 
ErbB1 inhibitors also fail to block proliferation due to ErbB3 maintained activity 
29. In our case sustained ErbB2 activity explains the refractoriness of 
choriocarcinoma tumors to pure ErbB1 inhibitors.  
 ErbB2 lacks ligand-binding capacity and requires heterodimerization with 
other members of the family in order to be activated. In fact, due to its 
extracellular domain conformation, ErbB2 is the preferred partner and common 
subunit for the rest of ErbB members, and the more physiological dimers 
formed appear to be ErbB2-containing heterodimers 4, 30. Specific inhibitors of 
ErbB1 also reduce ErbB2 signalling in breast cancer cells 31-33. However, in our 
model pure ErbB1 inhibitors do not affect ErbB2 phosphorylation. Thus our 
results indicate that ErbB2 is active in our tumoral model preferentially due to 
the formation of ErbB2/ErbB3 heterodimers. Moreover, we have shown that 
ErbB3 activation is dependent on ErbB2 activity: Block of ErbB2 and ErbB1 
activation by the use of lapatinib completely inhibits ErbB3 phosphorylation, 
while pure ErbB1 inhibitors do not affect levels of active ErbB3. In tumors where 
both receptors are expressed, there appears to exist a mutual regulation. Thus, 
inactivation of ErbB2 leads to decreased ErbB3 activation in breast cancer cells 
34, 35. On the other hand, ErbB3 is required for ErbB2 to transform breast cancer 
cells 36, 37. Moreover, in breast and bladder cancers, ErbB3 expression and 
activity correlate with ErbB2 expression 38-40. In the different testicular tumor 
models analyzed in this work there is a high correlation between ErbB2 and 
ErbB3 protein expression, confirming this mutual regulation also in germ cell 
tumors. Our results show that non seminoma testicular tumors are 
characterized by high levels of ErbB3 as compared to normal testicle. Despite 
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the fact that ErbB3 is not overexpressed or mutated in tumors, it seems to play 
an important role in facilitating transformation by other oncogenes (for example 
ErbB2) and participates in drug resistance 41. ErbB3 and its ligand neuregulin-1 
are expressed and play a role in germinal cells during development of fetal 
mouse gonads, where ErbB2 is also expressed 42, 43. Thus, overexpression of 
ErbB3 could be a consequence of an undifferentiated or poorly differentiated 
state of tumors; this possibility should be further explored in the future. 
Lapatinib has been approved by FDA for the treatment of ErbB2-positive 
metastatic breast cancer patients after trastuzumab-progression 44 and it is 
under clinical trials in different solid tumors. Our results in preclinical models 
indicate that lapatinib is also effective in choriocarcinoma testicular tumor. 
Sensitivity to lapatinib could be related to ErbB3 expression and the inhibition of 
ErbB2/ErbB3 heterodimer formation. In fact, cells with higher levels of ErbB1, 
as compared to ErbB2 and ErbB3, are more sensitive to pure ErbB1 inhibitors 
such as gefitinib, while cells with higher levels of ErbB2 and ErbB3 are more 
sensitive to lapatinib 45. Moreover, it has recently been described that certain 
tumor cells posses an autocrine loop: cells secrete high levels of neuregulin-1, 
which stimulates the formation and activity of ErbB2/ErbB3 heterodimers and 
downstream signalling pathways in the absence of ErbB2 amplification 46, 47. 
Growth of these cells can be inhibited by lapatinib 47, as is the case with our 
testicular tumor models. In contrast, lapatinib has no effect on lung cancer cells 
that show increased ErbB3 activation mediated by Met independently of ErbB2 
25. Finally, it is clear that other signalling pathways in addition to EGFs also play 
a role in testicular choriocarcinoma tumors that can explain the partial effect of 
lapatinib on tumor growth: c-Kit, CXCR4 or PDGFs, among others, also play a 
role in their physiology 17, 48 and could be responsible for tumor growth in the 
presence of lapatinib-mediated inhibition of EGF receptors. Combination with 
other drugs that block some of these other pathways might be an interesting 
therapeutical alternative. In fact, our results indicate a synergic effect between 
lapatinib and anti-angiogenic drugs (data not shown).  
In all, our results indicate that lapatinib could be a therapeutic alternative 
for the treatment of tumors where the heterodimer ErbB2/ErbB3 plays a key 
role, as in testicular germ cell tumors. Our data reinforces the concept that the 
presence of the different members of the ErbB family can predict the 
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effectiveness of a drug, and the analysis of ErbB1, ErbB2 and ErbB3 
expression levels in patient tumor biopsies before anti-ErbB targeted treatments 
should be recommended. 
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FIGURE LEGENDS 
 
Fig. 1: Lack of effect of pure ErbB1 receptor inhibitors cetuximab and 
gefitinib in a model of choriocarcinoma testicular germ cell tumor. 
A) Expression of ErbB1 and ErbB2 receptors and tubulin, as loading control, 
was analysed by western blotting of normal human testis (lane 1) and in 3 
independent embryonal carcinomas (lanes 2, 3 and 4), 1 yolk sac (lane 5), 2 
independent mixed heterogenous component tumors (lanes 6 and 7) and 2 
independent choriocarcinoma (lanes 8 and 9) testicular tumor xenograft models. 
B) Mice orthotopically implanted with the TGT38 choriocarcinoma were treated 
with vehicle, cetuximab or gefitinib as described in materials and methods. Final 
tumor volume was analysed. 
 
Fig. 2: ErbB1 inhibitors reduce ErbB1 but not ErbB2 phosphorylation 
levels. 
Densitometric quantification of A) phosphorylated ErbB1 relative to total ErbB1 
and B) phosphorylated ErbB2 relative to total ErbB2 are shown as the mean ± 
SD of four control tumors, four cetuximab-treated tumors and five gefinitib-
treated tumors, represented as arbitrary units relative to control group mean. ∗, 
p < 0.05.  
Densitometric quantifications of C) phosphorylated AKT relative to total AKT, D) 
phosphorylated Erk1/2 relative to total Erk1/2 and E) phosphorylated Stat3 
relative to actin are shown. Results are the mean ± SD of four control tumors, 
four cetuximab-treated tumors and five gefitinib-treated tumors relative to 
control group mean.  
 
Fig. 3: The dual ErbB1 and ErbB2 inhibitor lapatinib inhibits tumor growth 
in a model of choriocarcinoma testicular germ cell tumor. 
A) Mice bearing the orhotopically implanted TGT38 tumor were treated with 
vehicle or lapatinib, as described in materials and methods, and tumor volume 
was analysed. 
B and C) Sections from control and treated tumors were stained for the 
proliferation marker Ki67 and TUNEL, an apoptotic staining assay. B) 
Percentage of tumor Ki67 positive cells is expressed relative to control group. 
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Results are the mean + SD of four control and three lapatinib treated tumors. C) 
Results are expressed as the percentage of TUNEL staining-positive nuclei 
relative to the control group, and are the mean + SD of three control and three 
lapatinib treated tumors, ∗, p < 0.05.  
 
Fig. 4: Lapatinib blocks ErbB1 and ErbB2 phosphorylation and dowstream 
signalling pathways.  
A) Expression of phosphoErbB1 (pErbB1), total ErbB1, phosphoErbB2 
(pErbB2), total ErbB2 and actin were analysed by western blot in lapatinib-
treated and control tumors. A representative blot showing results obtained for 
four independent control tumors and five independent lapatinib-treated tumors 
is shown.  
Densitometric quantifications of B) phosphorylated ErbB1 relative to total 
ErbB1, C) phosphorylated ErbB2 relative to total ErbB2, D) phosphorylated AKT 
relative to total AKT, E) phosphorylated Erk1/2 relative to total Erk1/2, and F) 
phosphorylated Stat3 relative to actin are shown. Results are the mean ± SD of 
four control tumors and six lapatinib-treated tumors, and are represented as 
arbitrary units relative to the control group. ∗, p < 0.05; ∗∗, p<0.01. 
 
Fig. 5: ErbB3 is overexpressed in patient testicular tumoral samples and 
in their derived orthotopic models. 
A) mRNA levels of human ErbB1, ErbB2, ErbB3 and ErbB4 were analyzed by 
quantitative real-time PCR. Results are expressed as the mean + SD of mRNA 
expression in seven TGT38 tumors relative to mRNA expression levels in four 
normal human testis. 
B) The protein expression of ErbB1, ErbB2, ErbB3 and tubulin, as loading 
control, was analyzed by western blotting in three independent human testicular 
samples and four independent TGT38 tumor lysates.  
C) Expression of ErbB3 and ErbB4 receptors and tubulin were analysed by 
western blotting in normal human testis (lane 1), in 3 independent embryonal 
carcinomas (lanes 2, 3 and 4), 1 yolk sac (lane 5), 2 independent mixed 
heterogenous component tumors (lanes 6 and 7) and 2 independent 
choriocarcinoma (lanes 8 and 9) testicular tumor xenograft models. 
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D) Histologic and immunohistochemical characterization of primary tumors and 
their respective orthotopically implanted xenografts in nude mice (TGT: TGT12 
for embryonal carcinoma, TGT1 for yolk sac and TGT38 for choriocarcinoma): 
(A, E, I, M, Q, U) Hematoxilin-eosin staining; (B, F, J, N, R, V) ErbB1 
immunostaining; (C, G, K, O, S, W) ErbB2 immunostaining; (D, H, L, P, T, X) 
ErbB3 immunostaining. (400x; bar: 100µm). 
 
Fig. 6: ErbB3 forms heterodimers with ErbB2 in TGT38 tumors and ErbB3 
activity is blocked by lapatinib but not by ErbB1 pure inhibitors. 
A and B) ErbB1, ErbB2 and ErbB3 detection in ErbB1 (A) and ErbB2 (B) 
immunoprecipitates from TGT38 tumor lysates was carried out by western blot; 
proteins were also analyzed in total tumor lysates (input). While low levels of 
ErbB3 were detected in ErbB1-immunoprecipitates, high ErbB3 levels were 
detected in the ErbB2-immunoprecipitates; the presence of ErbB1 or ErbB2 in 
the correspondent precipitates demonstrates the efficacy of the 
immunoprecipitation protocol. 
C and D) PhosphoErbB3, total ErbB3 and actin expression were analyzed by 
Western blotting in independent tumors from the treatments with C) vehicle and 
lapatinib and D) vehicle, cetuximab and gefitib. Representative blots shows the 
results obtained.  
E and F) Densitometric quantifications of phosphorylated ErbB3 relative to total 
ErbB3 in tumors from both treatments are represented as arbitrary units relative 
to control group. Results are the mean ± SD of E) four control tumors and six 
lapatinib-treated tumors and F) four control tumors, four cetuximab treated-
tumors and five gefitinib-tretated tumors. ∗∗ p<0.01. 
 
 
 






